PIK3CA and cancer: Given that HGSOC often has a low mutation rate in the PI3K/Akt pathway and shows limited response to copanlisib alone, combining copanlisib with cerivastatin could represent a promising strategy to improve outcomes in cancers with inherently low pAkt levels.